Celltrion’s autoimmune disease treatment Steqeyma (ustekinumab) is set to be sold at Costco pharmacies across the U.S. under a new listing agreement with Costco Health Solutions, the pharmacy benefit manager (PBM) arm of the retailer.
Celltrion’s Stelara biosimilar, Steqeyma, is set to replace the original on Costco’s formulary.
Celltrion’s Stelara biosimilar, Steqeyma, is set to replace the original on Costco’s formulary.
As part of the agreement, Steqeyma has been designated a preferred drug, which typically gives it high-tier placement in insurer formularies and priority in prescribing decisions. The original product, Janssen’s Stelara, will be removed from Costco’s formulary, according to a Celltrion spokesperson.
The contract enables Steqeyma to be reimbursed at Costco pharmacies nationwide for PBM members and Costco employees. Reimbursement is expected to begin within three to six months, depending on the PBM.
“Steqeyma will soon be available through pharmacies at Costco, a major U.S. retailer, and we are also finalizing listing agreements with large PBMs,” said Thomas Nusbickel, chief commercial officer of Celltrion USA.
Steqeyma launched in the U.S. earlier this month with a low wholesale acquisition cost (WAC) version priced at an 85 percent discount to the originator. Celltrion said the pricing strategy is intended to accommodate large PBMs, smaller PBMs with limited rebate negotiating power, and uninsured patients.
Related articles
Celltrion expands market presence in Italy with autoimmune disease biosimilars
Celltrion's denosumab biosimilar lands in Korea at 28% discount to Prolia
Celltrion pledges 30% CAGR by 2027 with major shareholder returns
Celltrion launches Steqeyma in US with 85% discount strategy to boost market access
Samsung Bioepis launches Stelara biosimilar in US to expand treatment options
Celltrion launches Stelara biosimilar in France, completing rollout in Europe ahead of US debut
Celltrion releases Stelara biosimilar in Germany, Netherlands
Dong-A ST’s Stelara biosimilar Imuldosa scores FDA approval
Kim Ji-hye jkim404@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited